title: Glycosylation profiles of therapeutic antibody pharmaceuticals.
abstract: Recombinant antibodies specific for human targets are often used as therapeutics and represent a major class of drug products. Their therapeutic efficacy depends on the formation of antibody complexes resulting in the elimination of a target molecule or the modulation of specific signalling pathways. The physiological effects of antibody therapeutics are known to depend on the structural characteristics of the antibody molecule, specifically on the glycosylation which is the result of posttranslational modifications. Hence, production of therapeutic antibodies with a defined and consistent glycoform profile is needed which still remains a considerable challenge to the biopharmaceutical industry. To provide an insight into the industries capability to control their manufacturing process and to provide antibodies of highest quality, we conducted a market surveillance study and compared major oligosaccharide profiles of a number of monoclonal antibody pharmaceuticals sampled on the Swiss market. Product lot-to-lot variability was found to be generally low, suggesting that a majority of manufacturers have implemented high quality standards in their production processes. However, proportions of G0, G1 and G2 core-fucosylated chains derived from different products varied considerably and showed a bias towards the immature agalactosidated G0 form. Interestingly, differences in glycosylation caused by the production cell type seem to be of less importance compared with process related parameters such as cell growth.
authors: Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland.
authors: Christoph
authors: C
authors: Wacker
authors: Christoph N
authors: CN
authors: Berger
authors: Philippe
authors: P
authors: Girard
authors: Roger
authors: R
authors: Meier
mesh_terms: D000818:Animals; D001702:Biopharmaceutics / Q000379:methods / Q000592:standards; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D019075:Electrophoresis, Capillary; D006031:Glycosylation; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry* / Q000378:metabolism; D051379:Mice; D009844:Oligosaccharides / Q000737:chemistry / Q000378:metabolism; D015202:Protein Engineering; D011499:Protein Processing, Post-Translational; D011786:Quality Control; D013678:Technology, Pharmaceutical
chemical_list: D007074:Immunoglobulin G; D009844:Oligosaccharides